Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 4/20 | 0.70 |
| ▸ | PKN1 | Q16512 | 4/20 | 0.70 |
| ▸ | PAK4 | O96013 | 3/20 | 0.70 |
| ▸ | PAK3 | O75914 | 3/20 | 0.70 |
| ▸ | PAK2 | Q13177 | 3/20 | 0.70 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.70 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.70 |
| ▸ | TNK2 | Q07912 | 7/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.51 |
| ▸ | NOD2 | Q9HC29 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | WEE1 | P30291 | 3/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15030469 | 0.93 | PAK1 (0.82) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL15041839 | 0.91 | PAK1 (0.68) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL15035986 | 0.88 | PAK1 (0.70) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL15030471 | 0.87 | PAK4 (0.75) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL14681960 | 0.84 | PAK1 (0.71) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL13554100 | 0.84 | PKN1 (0.66) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL13553518 | 0.84 | PAK1 (0.68) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL13553523 | 0.84 | PAK1 (0.66) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL15035981 | 0.84 | PKN1 (0.59) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL29504158 | 0.83 | PAK1 (1.00) | PAK1PKN1PAK4PAK3PAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK3 | PAK1 6/4885PKN1 534/4885PAK4 5/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | PAK1 4/4885PKN1 326/4885PAK4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.